Clinical Trial Search

Primary: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline — 1.1; .9 score on a scale

Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)

Primary: Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI) — 7.47 percent change

Primary: Maximum Plasma Concentration (Cmax) — 1020; 1100 ng/mL

Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819

Primary: FCI Score at Follow-up — 147.3; 164.0; 123.3; 150.8 points awarded for correct items

Primary: ADAS-Cog-Exec Global Composite — -0.146; -0.068 Change score — p=0.29

Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Brain Glucose Consumption — 27.9; 28.1 umol/100 g/min

Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC

Primary: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase…

Primary: Change From Baseline in CSF Abeta42 — 4.8; 12.5; 16.2 pg/mL — p=0.087

Primary: One-card Learning (OCL) Measurement Over 12 Weeks of Treatment — 0.954; 0.942; 0.822; 0.969 Score on a scale

Primary: Face-name Memory Test Performance — -.28; -.01; -1.29; -1.76 pairs correctly recalled/recognized

Primary: Part 2: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 91.5; 95.4; 24.8; 38.0 Percentage of Participants

Primary: The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint). — 13; 10; 13; 9 participants

Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 97.2; 93.3; 90.0; 91.4 percentage of participants

Primary: Change in Total Recall Score in the Selective Reminding Test — 5.7; 9.4 score on a scale — p=0.05

Primary: Geriatric Depression Scale — 2.6; 2.1; 2.8; 1.9 score on a scale

Primary: Number of Participants With an Improvement of ≥ 4 Points on the ADAS-cog/11 — 0 responders

Primary: Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) — -0.09679; -0.15776 Z-score — p=0.564

Primary: Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo — 14; 21 Participants — p=<0.16

Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 6; 11; 4; 7 Participants

Primary: Acute Safety — 2 participants

Primary: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) — 49; 81; 106; 32.5 units on a scale

Primary: Blood Biomarkers of Pharmacodynamic Response- Cytokines — 26.672; 190.829; 20.309; 2293.879 picogram/milliliter (pg/ml)

Primary: Hopkins Verbal Learning Test-Revised (HVLT-R) — 23.52; 20.04; 23.68; 20.39 score on a scale

Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections

Primary: Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) — 1; 9 Participants — p=.02